– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology –
– Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment –
– Cash position of $95.1 million supports operations through 2025 –
LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and recent business highlights.
“During the second quarter we shared interim Phase I/IIa data from our ongoing CHIRON and THETIS TIL-based cNeT clinical trials and established an important research collaboration with Arcturus Therapeutics to explore the use of clonal neoantigens in second-generation personalized mRNA cancer vaccines”, said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. “Our insights into the factors that drive durable engraftment and immune evasion led us to add an additional cohort in the CHIRON and THETIS trials to evaluate cNeT persistence and clinical activity in patients with enhanced host conditioning (EHC). These findings, along with the cancer vaccine research collaboration, continue to illustrate the potential value of our platform, including the unparalleled capability of PELEUS to select tumor targets with the highest potential for immune system recognition in a variety of modalities including TIL, neoantigen vaccines, ADCs, and TCR-T therapies.
Our financial position remains strong with more than $95 million in cash, which we expect to support operations through 2025, including the completion of the ongoing Phase I/IIa trials and the Arcturus collaboration.”
Clinical and Business Updates
Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines
Combines Achilles’ AI-powered, tumor-targeting technology with Arcturus’ self-amplifying mRNA platform
Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies
Provided an interim Phase I/IIa update on the use of clonal neoantigen reactive T cells (cNeT) in advanced NSCLC and melanoma
Dosed first EHC patients in CHIRON and THETIS, with the first three EHC patients showing improved cNeT persistence and engraftment
Delivered 10 products containing over 100 million cNeT and five containing over one billion cNeT
Matilde Saggese, MD, has been appointed as Interim Chief Medical Officer. Dr. Saggese has served as Vice President and Medical Director of Achilles Therapeutics since March 2021.
Financial Highlights
Cash and cash equivalents: Cash and cash equivalents were $95.1 million as of June 30, 2024, as compared to $131.5 million as of December 31, 2023. The Company believes that its cash and cash equivalents are sufficient to fund its planned operations through 2025.
Research and development (R&D) expenses: R&D expenses were $13.6 million for the second quarter ended June 30, 2024, compared to $13.8 million for the second quarter ended June 30, 2023. The decrease was primarily driven by decreased activity in THETIS and lower personnel costs, partially offset by increased activity in CHIRON.
General and administrative (G&A) expenses: G&A expenses were $4.2 million for the second quarter ended June 30, 2024, compared to $4.3 million for second quarter ended June 30, 2023. This decrease was primarily driven by lower personnel costs and lower insurance premiums.
Net loss: Net loss for the second quarter ended June 30, 2024 was $16.4 million or $0.41 per share compared to $16.8 million or $0.42 per share for the second quarter ended June 30, 2023.
2024 Focus
Clinical Data: Report clinical activity and translational science data from patients in CHIRON and THETIS, evaluating the benefit of EHC, with a meaningful data update expected in the second half of 2024
Arcturus Collaboration: Ongoing evaluation of best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens with the potential to generate IND-enabling data
Translational Science: Leverage the Company’s unique bioinformatics platform to better understand the drivers associated with clinical responses
Manufacturing Development: Continue VELOS™ and PELEUS™ development to optimize cNeT dose and functionality
About Achilles Therapeutics Achilles is a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Forward Looking Statements This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing of the Company’s clinical and translational data updates and the Company’s beliefs about recent data updates, and expectations related to the Company’s cash runway and operating expenses and capital expense requirements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
June 30,
December 31,
2024
2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
95,111
$
131,539
Prepaid expenses and other current assets
22,706
14,094
Total current assets
117,817
145,633
Property and equipment, net
6,954
9,171
Operating lease right of use assets
4,165
4,372
Deferred tax assets
41
41
Restricted cash
53
33
Other assets
2,156
2,206
Total non-current assets
13,369
15,823
Total assets
$
131,186
$
161,456
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable
$
2,865
$
5,629
Accrued expenses and other liabilities
7,225
7,828
Operating lease liabilities - current
4,205
3,539
Total current liabilities
14,295
16,996
NON-CURRENT LIABILITIES:
Operating lease liabilities - non-current
258
1,076
Other long-term liability
1,158
1,015
Total non-current liabilities
1,416
2,091
Total liabilities
15,711
19,087
Commitments and contingencies
SHAREHOLDERS’ EQUITY:
Ordinary shares, £0.001 par value; 41,087,901 and 41,082,948 shares authorized, issued and outstanding at June 30, 2024 and December 31, 2023, respectively
54
54
Deferred shares, £92,451.85 par value, one share authorized, issued and outstanding at June 30, 2024 and December 31, 2023, respectively
128
128
Additional paid in capital
417,914
415,210
Accumulated other comprehensive income
(14,015
)
(13,071
)
Accumulated deficit
(288,606
)
(259,952
)
Total shareholders’ equity
115,475
142,369
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
$
131,186
$
161,456
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
Three Months Ended
Six Months Ended
June 30,
June 30,
2024
2023
2024
2023
OPERATING EXPENSES:
Research and development
$
13,635
$
13,774
$
23,775
$
27,642
General and administrative
4,164
4,318
8,323
9,003
Total operating expenses
17,799
18,092
32,098
36,645
LOSS FROM OPERATIONS:
(17,799
)
(18,092
)
(32,098
)
(36,645
)
OTHER INCOME (EXPENSE), NET:
Other income (expense)
1,427
1,212
3,429
2,303
Total other income (expense), net
1,427
1,212
3,429
2,303
Loss before income taxes
(16,372
)
(16,880
)
(28,669
)
(34,342
)
(Provision) benefit for income taxes
(8
)
34
15
(10
)
Net loss
(16,380
)
(16,846
)
(28,654
)
(34,352
)
Other comprehensive (loss) income:
Foreign exchange translation adjustment
195
3,817
(944
)
7,794
Comprehensive loss
$
(16,185
)
$
(13,029
)
$
(29,598
)
$
(26,558
)
Net loss per share attributable to ordinary shareholders—basic and diluted
$
(0.41
)
$
(0.42
)
$
(0.71
)
$
(0.86
)
Weighted average ordinary shares outstanding—basic and diluted
